Circulating microparticles in carriers of factor V leiden with and without a history of venous thrombosis

Thrombosis and Haemostasis

Volumn 108, Issue 4, 2012, Pages 633-639

  Campello, Elena ^a   Spiezia, Luca ^a   Radu, Claudia M ^a   Bon, Maria ^a   Gavasso, Sabrina ^a   Zerbinati, Patrizia ^a   Woodhams, Barry ^b   Tormene, Daniela ^a   Prandoni, Paolo ^a   Simioni, Paolo ^a  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^b Diagnostica Stago   (France)

Author keywords

Factor V leiden; Microparticles; Tissue factor bearing microparticles; Venous thromboembolism

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; LIPOCORTIN 5; PROCOAGULANT;

ACTIVATED PROTEIN C RESISTANCE; ADULT; AGED; ARTICLE; BLOOD CLOTTING TIME; CONTROLLED STUDY; ENDOTHELIAL MICROPARTICLE; FEMALE; HUMAN; LEUKOCYTE MICROPARTICLE; MAJOR CLINICAL STUDY; MALE; MEMBRANE MICROPARTICLE; PLATELET MICROPARTICLE; PRIORITY JOURNAL; TISSUE FACTOR BEARING MICROPARTICLE; VEIN THROMBOSIS;

ADULT; AGED; CASE-CONTROL STUDIES; CELL-DERIVED MICROPARTICLES; COHORT STUDIES; FACTOR V; FEMALE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; VENOUS THROMBOSIS;

EID: 84867281947     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH12-05-0280     Document Type: Article

References (40)

1. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67.
2. Rosendaal FR, Koster T, Vandenbroucke JP, et al. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 85: 1504-1508.
3. Simioni P, Sanson BJ, Prandoni P, et al. Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost 1999; 81: 198-202.
4. Lensen RP, Bertina RM, de Ronde H, et al. Venous thrombotic risk in family members of unselected individuals with factor V Leiden. Thromb Haemost 2000; 83: 817-821.
5. Juul K, Tybjaerg-Hansen A, Schnohr P, et al. Factor V Leiden and the risk for venous thromboembolism in the adult Danish population. Ann Intern Med 2004; 140: 330-337.
6. Segers O, Simioni P, Tormene D, et al. Genetic Modulation of the FV(Leiden) /normal FV Ratio and Risk of Venous Thrombosis in FV Leiden Heterozygotes. J Thromb Haemost 2012; 10: 73-80.
7. Rosendaal FR. Risk factors for venous thrombotic disease. Thromb Haemost 1999; 82: 610-619.
8. Heit JA, Sobell JL, Li H, et al. The incidence of venous thromboembolism among Factor V Leiden carriers: a community-based cohort study. J Thromb Haemost 2005; 3: 305-311.
9. Chirinos JA, Heresi GA, Velasquez H, et al. Elevation of endothelial microparticles, platelets, and leucocyte activation in patients with venous thromboemoblism. J Am Coll Cardiol 2005; 45: 1467-1471.
10. Ay C, Freyssinet JM, Sailer T, et al. Circulating procoagulant microparticles in patients with venous thromboembolism. Thromb Res 2009; 123: 724-726.
11. Owens III AP, Mackman N. Microparticles in Hemostasis and Thrombosis. Circ Res 2011; 108: 1284-1297.
12. Garcia Rodriguez P, Eikenboom HCJ, Tesselaar MET, et al. Plasma levels of microparticles-associated tissue factor activity in patients with clinically suspected pulmonary embolism. Thromb Res 2010; 126: 345-349.
13. Tesselaar ME, Romijn FP, Van der Linden IK, et al. Microparticle-associated tissue factor activity in cancer patients with and without thrombosis. J Thromb Haemost 2009; 7: 1421-1423.
14. Manly DA, Wang J, Glover SL, et al. Increased microparticle tissue factor activity in cancer patients with venous thromboembolism. Thromb Res 2010; 125: 511-512.
15. Furie B, Furie BC. Role of platelet P-selectin and microparticle PSGL-1 in thrombus formation. Trends Mol Med 2004; 10: 171-178.
16. Morel O, Toti F, Hugel B, et al. Procoagulant microparticles disrupting the vascular homeostasis equation? Arterioscler Thromb Vasc Biol 2006; 26: 2594-2604.
17. Mathivanan S, Ji H, Simpson RJ. Exosomes: extracellular organelles important in intercellular communication. J Proteomics 2010; 73: 1907-1920.
18. Perez-Casal M, Downey C, Fukudome K, et al. Activated protein C induces the release of microparticle-associated endothelial protein C receptor. Blood 2005; 105: 1515-1522.
19. Enjeti AK, Lincz LF, Scorgie FE, et al. Circulating microparticles are elevated in carriers of Factor V Leiden. Thromb Res 2010; 126: 250-253.
20. Wagner C, Dati F. Fibrinogen. In: Clinical Laboratory Diagnostics. Frankfurt THBooks Verlagsgesellschaft 1998: 609-612.
21. Fickenscher K. Analysis of individual coagulation factors. In: Clinical Laboratory Diagnostics. Frankfurt TH-Books Verlagsgesellschaft 1998; pp. 607-609.
22. Simioni P, Scudeller A, Radossi P, et al. Pseudo-homozygous activated protein C resistance due to double heterozygous factor V defects (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: report of two cases belonging to two unrelated kindreds. Thromb Haemost 1996; 75: 422-426.
23. Simioni P, Prandoni P, Lensing AWA, et al. The risk of recurrent venous thromboembolism in patients with an Arg506 --- Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med 1997; 336: 399-403.
24. Campello E, Spiezia L, Radu CM, et al. Endothelial, platelet and tissue facrot-bearing microparticles in cancer patients with and without venous thrombembolism. Thromb Res 2011; 127: 473-477.
25. Robert S, Poncelet P, Lacroix R, et al. Standardization of platelet-derived microparticle counting using calibrated beads and a Cytomics FC500 routine cytometer: a first step towards multicenter studies? J Throm Haemost 2008; 7: 190-197.
26. van Dreden P, Rousseau A, Fontaine S, et al. Monitoring patient plasma plateletderived procoagulant microparticles (PMP) with a new factor Xa-based clotting test (XaCT). Blood Coag Fibrinolysis 2009; 20: 494-502.
27. Noubouossie DC, Lê PQ, Rozen L, et al. Evaluation of the procoagulant activity of endogenous phospholipids in the platelet-free plasma of children with sickle cell disease using functional assays. Thromb Res 2011; epub ahead of print.
28. Simioni P, Tormene D, Prandoni P, et al. Incidence of venous thromboembolism in asymptomatic family members who are carriers of factor V Leiden: a prospective cohort study. Blood 2002; 99: 1938-1942.
29. Lincz LF, Lonergan A, Scorgie FE, et al. Endogenous thrombin potential for predicting risk of venous thromboembolism in carriers of factor V Leiden. Pathophysiol Haemost Thromb 2006; 35: 435-439.
30. Curvers J, Thomassen MC, Rimmer J, et al. Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test. Thromb Haemost 2002; 88: 5-11.
31. Tans G, van Hylckama Vlieg A, Thomassen MC, et al. Activated protein C resistance determined with a thrombin generation- based test predicts for venous thrombosis in men and women. Br J Haematol 2003; 122: 465-470.
32. Couturaud F, Duchemin J, Leroyer C, et al. Thrombin generation in first-degree relatives of patients with venous thromboembolism who have factor V Leiden. A pilot study. Thromb Haemost 2008; 99: 223-228.
33. Lawrie AS, Albanyan A, Cardigan RA, et al. Microparticles sizing by dynamic light scattering in fresh-frozen plasma. Vox Sang 2009; 96: 206-212.
34. Chandler WL, Yeung W, Tait JF. A new microparticle size calibration standard for use in measuring smaller microparticles using a new flow cytometer. J Thromb Haemost 2011; 9: 1216-1224.
35. Ayers L, Kohler M, Harrison P, et al. Measurement of circulating cell derived microparticles by flow cytometry: sources of variability within the assay. Thromb Res 2011; 127: 370-377.
36. Lacroix R, Robert S, Poncelet P, et al. Standardization of platelet-derived microparticle enumeration by flow cytometry with calibrated beads: results of the International Society on Thrombosis and Haemostasis SSC Collaborative workshop. J Thromb Haemost 2010; 8: 2571-2574.
37. Rautou PE, Vion AC, Amabile N, et al. Microparticles, Vascular Function, and Atherothrombosis. Circ Res 2011; 109: 593-606.
38. Puddu P, Puddu GM, Cravero E, et al. The involvement of circulating microparticles in inflammation, coagulation and cardiovascular diseases. Can J Cardiol 2010; 26: 140-145.
39. Marchiori A, Mosena L, Prins MH, et al. The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies. Haematologica 2007; 92: 1107-1114.
40. Segal JB, Brotman DJ, Necochea AJ, et al. Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review. J Am Med Assoc 2009; 301: 2472-2485.